- Home
- GWRE vs GMAB Comparison
GWRE vs GMAB Comparison
Compare GWRE & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GWRE
- GMAB
- Stock Information
- Founded
- GWRE 2001
- GMAB 1999
- Country
- GWRE United States
- GMAB Denmark
- Employees
- GWRE N/A
- GMAB N/A
- Industry
- GWRE Computer Software: Prepackaged Software
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- GWRE Technology
- GMAB Health Care
- Exchange
- GWRE Nasdaq
- GMAB Nasdaq
- Market Cap
- GWRE 20.6B
- GMAB 17.4B
- IPO Year
- GWRE 2012
- GMAB N/A
- Fundamental
- Price
- GWRE $219.66
- GMAB $30.40
- Analyst Decision
- GWRE Buy
- GMAB Strong Buy
- Analyst Count
- GWRE 14
- GMAB 6
- Target Price
- GWRE $270.77
- GMAB $40.40
- AVG Volume (30 Days)
- GWRE 699.9K
- GMAB 2.6M
- Earning Date
- GWRE 12-04-2025
- GMAB 11-06-2025
- Dividend Yield
- GWRE N/A
- GMAB N/A
- EPS Growth
- GWRE N/A
- GMAB 132.41
- EPS
- GWRE 0.81
- GMAB 25.10
- Revenue
- GWRE $1,202,459,000.00
- GMAB $3,845,670,022.00
- Revenue This Year
- GWRE $18.42
- GMAB $24.92
- Revenue Next Year
- GWRE $15.10
- GMAB $15.97
- P/E Ratio
- GWRE $270.91
- GMAB $1.21
- Revenue Growth
- GWRE 22.64
- GMAB 29.57
- 52 Week Low
- GWRE $165.09
- GMAB $17.24
- 52 Week High
- GWRE $272.60
- GMAB $33.65
- Technical
- Relative Strength Index (RSI)
- GWRE 34.10
- GMAB 57.24
- Support Level
- GWRE $213.25
- GMAB $28.08
- Resistance Level
- GWRE $219.87
- GMAB $29.35
- Average True Range (ATR)
- GWRE 6.26
- GMAB 0.69
- MACD
- GWRE -3.10
- GMAB -0.07
- Stochastic Oscillator
- GWRE 14.97
- GMAB 98.73
About GWRE Guidewire Software Inc.
Guidewire Software provides cloud-based software solutions for property and casualty insurers. The flagship product, InsuranceSuite is a system of record and comprises ClaimCenter, a claims management system; PolicyCenter, a policy management system including policy definitions, quotas, issuance, maintenance, and renewal; and BillingCenter, for billing management, payment plans, and agent commissions. The company also offers InsuranceNow, a midmarket offering, as well as a variety of other add-on applications and services.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.